In this issue:
Increased risk of infections in SMM vs MGUS
Real-world risk of infection in patients undergoing front-line daratumumab-based therapy
Talquetamab treatment does not impair humoral immunity
TLG improves prognostication in patients with extramedullary disease
Factors impacting renal recovery in myeloma patients with CAN-related acute renal failure
Brilliant finds no significant cognitive decline after transplant
Linvoseltamab bests teclistamab for RRMM in indirect comparison
Risk of second primary malignancy with lenalidomide may have been inflated
Transcriptional plus genetic profiling virtually eliminates cases of FHR disease
Promising efficacy for talquetamab + daratumumab for RRMM
Expert contributor
Professor Philip Campbell is a general haematologist with broad training and experience in malignant and non-malignant haematology. His main clinical interests are malignant haematology and clinical research, particularly multicentre collaborative research in malignant haematology. His current appointments are Clinical Associate Professor, Deakin University Medical School, and Clinical Haematologist, Andrew Love Cancer Centre, Geelong Hospital, Barwon […]
Stay up to date with our latest clinical information.
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.